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Abstract. Saturated (SFA) and monounsaturated (MUFA)
fatty acids, the most abundant fatty acid species, have many
divergent biological effects including the regulation of cell
proliferation, programmed cell death and lipid-mediated
cytotoxicity. Their distribution is regulated by Stearoyl-CoA
Desaturases (SCD), the enzymes that convert SFA into
MUFA. A positive correlation between high levels of tissue
MUFA and several types of cancer has been reported, but a
causal relationship between the function of SCD1, the main
human SCD isoform, and cancer development has not yet
been firmly established. Here we report that the stable
knockdown of SCD1 gene expression in A549 human lung
adenocarcinoma cells decreased the ratio MUFA/SFA in total
lipids and inhibited the incorporation of glucose into cell
lipids. Cell proliferation and anchorage-independent growth
were considerably decreased in SCD1-depleted cells, whereas
the rate of apoptosis was elevated, with respect to control
A549 cells. In addition, phosphorylation of Akt-Ser473 and
GSK-3ß-Ser9 was found notably impaired in SCD1-ablated
A549 cells. Interestingly, the effects of SCD1 blockade on
Akt activation, cancer cell growth and apoptosis could not be
reversed by exogenously added oleic acid. Remarkably, the
reduction of SCD1 expression in lung cancer cells significantly
delayed the formation of tumors and reduced the growth rate
of tumor xenografts in mice. Our study demonstrates that
SCD1 activity regulates Akt activation and determines the rate
of cell proliferation, survival and invasiveness in A549 cancer
cells and shows, for the first time, that SCD1 is a key factor in
the regulation of tumorigenesis in vivo.
Introduction
Lung cancer is the leading cause of cancer death in the US
and one of the most deadly forms of cancer worldwide. The
vast majority of lung cancer (~80%) belongs to the histo-
pathological type of non-small cell lung cancer, with squamous
cell carcinomas and adenocarcinomas as the most prominent
forms (1). Since the 5-year survival rate of lung cancer remains
disappointingly low (~14%), it is clear that a thorough
understanding of the mechanisms of lung cancer development
is necessary in order to discover new therapeutic targets. In
this regard, lipid metabolism remains an under-studied area of
cancer research, although information on lipid perturbations
in cancer is mounting. For instance, a ubiquitous metabolic
alteration in several types of cancer cells occurs in the de novo
synthesis of fatty acids, the building blocks of cell
membrane-forming phospholipids and storage lipids such as
triacylglycerols and cholesteryl esters. While in normal cells
fatty acid synthesis is inhibited by exogenous fatty acids
uptaken from circulation, cancer cells display a high rate of
fatty acid synthesis, propelled by excess substrates supplied by
active glycolysis (2) and constitutively overexpressed fatty
acid synthase (FAS) (3). Increased de novo fatty acid synthesis
was shown in oncogene-transformed human cells (4) and in
several types of cancer cells including breast and prostate
cells (5-7). Importantly, the expression level of FAS has been
correlated with poor cancer prognosis (3).
Notably, while two main products of de novo fatty acid
synthesis and elongation, palmitic and stearic acids, are
abundant in cancer cells, increased content of their monoun-
saturated fatty acid (MUFA) Δ9 desaturation products,
palmitoleic and oleic acids, respectively, were also observed in
transformed and cancer cells and tissues (8-10), suggesting
that the high rate of fatty acid synthesis in cancer is coupled to
the conversion of saturated fatty acids (SFA) into MUFA.
High levels of expression and activity of Stearoyl-CoA
Desaturase 1 (SCD1), the endoplasmic reticulum-resident Δ9
desaturase that converts SFA into MUFA (11), have been
reported in several types of cancers, including colonic and
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esophageal carcinoma, hepatocellular adenoma, in mammary
cancer cells as well as chemically induced tumors (12-15).
However, high expression of SCD1 in human cancer tissues
seems to be not universal. In histopathological studies of
cancerous prostate epithelium, despite the presence of high
levels of SREBP-1, a powerful activator of SCD1 gene
transcription (16,17), low levels of SCD1 have been reported
(18).
In vitro studies have provided new evidence of a causal
relationship between MUFA synthesis and several biological
features of the cancer phenotype. We have reported that
SV40-transformed human lung fibroblasts show significantly
increased protein and activity levels of SCD1 with respect to
their parental normal cell line (4), suggesting that a high rate
of MUFA synthesis is needed for an active production of
membrane lipids to sustain the fast replication rate of
transformed cells (19). We have also shown that SV40-
transformed human lung fibroblasts bearing a knockdown of
SCD1 exhibit a significant decrease in MUFA, cholesterol and
phospholipid synthesis (20). Moreover, it was also found that
SCD1 deficiency leads to a slower rate of cell proliferation, a
loss of anchorage-independent growth and higher rates of
ceramide-independent apoptosis, strongly indicating the
participation of SCD1 in the regulation of cell proliferation,
survival and invasiveness.
These observations in oncogene-transformed cells
prompted us to determine whether a reduction of SCD1
expression and, consequently, in the synthesis and content
of cellular MUFA would alter the in vitro and in vivo
neoplastic phenotype of human lung cancer cells. Additionally,
we wished to explore whether ablation of SCD1 expression
in cancer cells would alter the activity of lipid-sensitive
signaling pathways associated with cell growth, survival
and cancer, such as the Akt pathway, hence causing the
aforementioned phenotypical changes. Thus, in the present
study, we examined the effect of the knockdown of SCD1
gene expression on cell growth, programmed cell death and
the tumorigenic capacity of A549 cancer cells, a human
lung adenocarcinoma cell line widely used as a good model
for non-small cell lung cancer. The present results show that
SCD1-deficient A549 cells exhibit slower in vitro cell
proliferation, higher rates of apoptosis and impaired
anchorage-independent colony formation. This loss of in vitro
neoplastic phenotype was not reversed by exogenous oleic
acid, suggesting that an endogenous pool of MUFA must be
available for sustaining the biological alterations of lung
cancer cells. Importantly, the reduction of SCD1 expression
in A549 cells and in SV40-transformed cells promoted a
decrease in the phosphorylation of both Akt and its
downstream effector glycogen synthase kinase-3ß (GSK-3ß),
suggesting that SCD1 may regulate cancer cell growth and
survival by modulating the activity of the Akt signaling
pathway. When A549 cells with ablated SCD1 expression
were injected into mice, they exhibited not only a great
delay in the formation of tumors, but also a slower rate of
tumor growth. In summary, we report here that SCD1
appears to be an essential factor in the stepwise process
leading to the onset and progression of lung cancer, laying
the groundwork to explore the potential therapeutic
applications of targeting SCD1 to treat human cancers.
Materials and methods
Materials. A549 human lung adenocarcinoma cancer cells
were obtained from American Type Culture Collection
(Rockville, MD). Four to six week-old female NIH Swiss
nude nu/nu mice were obtained from the Laboratory Animal
Facility, University of La Plata School of Veterinary,
Argentina. Standard rodent chow was purchased from
Cargill-Grupo Pilar S.A, Argentina and sterilized by γ
radiation (25 kGray) at IONICS, Buenos Aires, Argentina.
Lipofectamine™, pcDNA3 plasmid, Geneticin™, cell
culture media and other culture reagents were from Invitrogen
Life Technologies (Carlsbad, CA). Restriction enzymes and
other molecular biology reagents were from Promega
(Madison, WI). [1-14C]Stearic acid, [14C]glucose and [6-3H]-
thymidine were from American Radiolabeled Chemicals, Inc.
(St. Louis, MO). Ultrafiltered fetal bovine serum (FBS), fatty
acid-free bovine serum albumin (BSA), mouse anti-ß-actin
monoclonal antibody, anti-mouse IgG peroxidase conjugate,
phosphatase and protease inhibitor cocktail were purchased
from Sigma (St. Louis, MO). Pure lipid standards were from
Doosan Serdary (Yongin, Korea). Palmitic and oleic acid
were from NuCheck Prep (Elysian, MN). Cell culture
supplies, silica gel 60 chromatography plates and analytical-
grade solvents were from Fisher Scientific (Morris Plains,
NJ). Polyclonal anti-SCD1 antibody was a generous gift of
Dr Jean-Baptiste Demoulin, Université Catholique de Louvain,
Belgium. Polyclonal antibodies anti-total or phosphorylated
Akt1/2/3 (Ser 473) and anti-pGSK-3ß (Ser 9) were from
Santa Cruz Biotechnologies and Cell Signaling, respectively.
Cell culture. A549 cells were routinely cultured in bicarbonate-
buffered minimum essential medium with Earle's salts
(MEM) with 10% heat-inactivated FBS, penicillin (100 U/ml),
streptomycin (10 μg/ml), 1% non essential amino acids and
1% MEM vitamin solution (growing medium), at 37˚C, 5%
CO2 and 100% humidity.
Stable knockdown of SCD1 gene expression. The construct
pcDNA3-hSCDas (for ‘human Stearoyl-CoA Desaturase
antisense’ cDNA) (20) was transfected into A549 cells using
Lipofectamine reagent according to the manufacturers'
instructions. Positively transfected cells were selected with
600 μg/ml Geneticin in a culture medium for 14 days.
Individual cell colonies (hSCDas) were then isolated using
cloning cylinders. One cell clone, hSCDas-α, with low levels
of SCD1 expression and activity was selected for performing
the experiments. Empty pcDNA3 vector was stably transfected
into A549 cells and these cells were considered the control cell
line.
Immunoblotting. Western blot analysis was performed, as
previously described (20). Polyclonal rabbit anti-human SCD1
(1:2000 dilution) or monoclonal mouse anti-ß-actin (1:5000
dilution) were used as primary antibodies. Anti-total or
phosphorylated Akt1/2/3 (Ser 473) and anti-pGSK-3ß (Ser 9)
were used in a 1:250-1:1000 and 1:1000 dilutions,
respectively. In some experiments, cells were cultured in
0.1% FBS for 24 h and incubated with 0.1 mM of palmitic or
oleic acid complexed with 0.5% fatty acid free BSA in 0.1%
SCAGLIA  and IGAL:  INHIBITION OF TUMOR FORMATION BY SCD1 GENE KNOCKDOWN840
839-850  12/9/08  12:48  Page 840
FBS supplemented media for 30 min before harvesting. The
fatty acid concentration in media was determined with the
NEFA C kit (Wako Chemicals, Richmond, VA).
Lipid extraction. Cell monolayers were washed twice with
ice-cold PBS and scraped from the petri dishes with two
additions of 1 ml ice-cold methanol. One ml of chloroform and
0.5 ml of distilled water were added in order to complete the
extraction of total lipids, as described by Bligh and Dyer (21).
Determination of SCD activity. Preconfluent cells (80-90%
confluency) were incubated with trace amounts (2.3 μM) of
[14C]stearic acid (0.25 μCi/dish) in culture medium containing
0.5% BSA for 6 h. At the end of the incubation, total cell
lipids were extracted as described. Total cellular lipids were
saponified and released fatty acids were then esterified with
10% BF3 in methanol for 3 h at 64˚C. The derivated methyl
esters were separated by argentation thin layer chromatography
(TLC) following the procedure of Wilson and Sargent (22),
using a solvent phase consisting of hexane:ethyl ether (90:10,
by vol). Pure stearic acid and oleic acid standards were run in
parallel to the samples. Fatty acid spots on TLC were detected
by radiometric scanning. Spots were scraped from the TLC
plate and quantified with a scintillation counter. The level of
[14C]oleic acid produced was calculated from specific activity
of [14C]stearic acid and normalized to cellular protein content.
Metabolic labeling. Preconfluent cells were incubated for 6 h
with 1 μCi/dish [14C]glucose, in 10% FBS MEM. At the end of
the labeling period, the radioactive medium was recovered and
cell monolayers were washed twice with 0.1% BSA in ice-cold
phosphate-buffered saline (PBS), in order to eliminate residual
label on the cell surface. Lipid extraction was carried out as
described above.
Lipid analysis. Analysis of radioactivity of neutral and polar
lipid species were carried out, as previously described (20).
Briefly, neutral and polar lipid species were separated on
silica gel 60 thin-layer chromatography (TLC) plates using
one-dimensional single development procedures. Neutral
lipid separation was carried out with hexane:ethylether:acetic
acid, 80:20:2 (by vol) as solvent system. Pure lipid standards
were seeded and run on the TLC plates in parallel to samples.
Individual [14C]labeled lipid-spots detected by radiometric
scanning were scraped into plastic vials and radioactivity
levels were determined in a liquid scintillation counter. The
amount of [14C] tracer incorporated in each lipid class was
calculated from the specific activity of each substrate and
normalized to cellular protein content. For the analysis of fatty
acid composition, methyl esters of fatty acids were obtained
as described above and analyzed by gas chromatography in a
Hewlett Packard HP6890 GC apparatus, fitted with a flame
ionization detector and equipped with an OmegaWax 250
capillary column. Chromatographic peaks were identified by
comparison of their retention times with those of pure fatty
acid standards and percent distribution was calculated.
Cell proliferation. To determine the growth rate of control and
hSCDas-α cell lines, 1.6x105 cells were seeded in triplicate
60-mm petri dishes. Twenty-four hours later, medium was
replaced with fresh medium. The medium was then changed
every two days. At different time points up to 144 h, cells
were trypsinized and counted in an hemocytometer. At all
time points, cell viability, as determined by the trypan blue
exclusion test, was 95% or higher.
[3H]Thymidine incorporation into cell DNA. The rate of DNA
synthesis of hSCDas-α and control cells was estimated by
determining the levels of [3H]thymidine incorporation into
DNA after pulsing the cells with the radiolabeled tracer for
2 h, followed by precipitation of total DNA and scintillation
counting, as described by Bagnato and Igal (19). Groups of
cells were incubated with 200 μM oleate for 48 h previous to
[3H]thymidine labeling.
Colony formation assay. Control and hSCDas-α cells were
plated at 1x104 cells per 60-mm dishes in quadruplicate in
MEM containing 10% FBS, in the presence or absence of
200 μM oleate and 0.3% (w/v) agar plated onto a bottom layer
of 0.6% (w/v) agar in MEM. After 4 weeks, cell colonies
were stained with ethidium bromide in PBS for 2 h and
photographed under UV light. Colonies were counted using
a Molecular Imager ChemiDoc XRS system (Bio-Rad
Laboratories, Hercules, CA).
Apoptosis analysis: fragmentation of [3H]thymidine-labeled
DNA. The determination of DNA fragmentation was performed
essentially as described by Venable et al (23). DNA samples
from preconfluent hSCDas-α cells and control cells were
labeled with 0.4 μCi [3H]thymidine in a regular growing
medium for 24 h. The medium was removed, the cell
monolayers were washed twice with PBS at 37˚C and cells
were allowed to grow for 24 h. Then, the chase medium
containing detached apoptotic cells was collected and the
[3H]radioactivity was determined in a scintillation counter.
Cell monolayers were lysed in PBS with 1% Triton X-100
and 0.2 μM EDTA, collected and sedimented by centrifugation
at 14,000 rpm for 15 min. Radioactivity was quantified in the
supernatant, containing fragmented [3H]DNA and in the
pellet containing the intact cellular DNA, which was washed
and resuspended in 1% Triton X-100 and 0.2 μM EDTA. The
levels of fragmented DNA was estimated according to the
following calculation: (chase medium DPM + supernatant
DPM)/total DPM.
Analysis of tumor formation. Four to six-week-old female
Swiss nude mice were maintained in isolators under pathogen-
free conditions and kept in a 12h/12h light/dark cycle. After a
15-day acclimatization period, mice were subcutaneously
inoculated in the interscapular space with 1x106 hSCDas-α or
control A549 cells resuspended in 0.1 ml PBS. Two
independent experiments were performed with five animals
per group and per experiment. The time of appearance of local
tumors was monitored by palpation. Tumor size was measured
weekly using caliper and tumor volume were calculated by
the equation a2 x b/2, where a is tumor width and b is tumor
height. Data are presented as mean relative tumor volume
where initial tumor volume is 1. After six weeks from tumor
appearance, mice were euthanized and tumors were excised for
further studies not reported here. Experimental protocols in
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animals were performed according to the Animal Welfare
Guidelines of NIH (INIBIOLP's Animal Welfare Assurance
No. A5647-01).
Determination of cellular protein. Total cellular protein
content was measured by Bradford method (Pierce), using
BSA as a standard.
Statistical analysis. Results from a representative experiment
with 3-5 samples per experimental group are presented as
means ± SD. Statistical significance of the data was
determined by Student's t-test or one-way ANOVA followed
by the Bonferroni test.
Results
Stable ablation of SCD1 expression reduces MUFA and
increases SFA in total cell lipids. Previously, we reported that
the knockdown of SCD1 gene expression in SV40-transformed
human lung fibroblasts led to either reduction or suppression
of several parameters of neoplastic behavior in vitro (20). In
order to test whether ablation of SCD1 expression in human
cancer cells may affect in vivo tumor formation, we generated
a model of SCD1 depletion in A549 human lung adeno-
carcinoma cells. To do so, A549 cells were stably transfected
with a plasmid containing a fragment of human SCD1 cDNA
in an antisense orientation (hSCDas cells) or with the empty
vector (control cells). After clonal selection, SCD activity and
protein levels were estimated in SCDas cell colonies. In one
selected colony (hSCDas-α), SCD activity was significantly
diminished (~20%) with respect to mock-transfected A549
cells (control) (Fig. 1A). The reduction in SCD activity was
caused by lower levels of SCD1 protein (Fig. 1B). The
observation that stable knockdown of SCD1 expression was
unable to produce cell colonies with an inhibition of SCD1
expression and activity >20% in cancer cells is puzzling and
may indicate that, due to selection pressure, cells with more
reduced SCD1 expression may not be viable. Nevertheless, as
described below, this modest degree of SCD1 inhibition was
sufficient for promoting significant changes in the biochemical
and biological phenotype of cancer cells.
As a result of SCD1 reduction, the distribution of fatty acid
species in total cellular lipids of SCD1-ablated cells was
considerably altered (Table I). The main products of SCD
activity, palmitoleic and oleic acids, were diminished by 23 and
17%, respectively, in hSCDas-α cells compared to controls.
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Figure 1. Reduced SCD activity and protein levels in hSCDas-α cells. Δ9-desaturating activity (A) was determined in the control and hSCDas-α cells by incubating
near confluent cell monolayers with [14C]stearic acid (0.25 μCi/dish) for 6 h in 10% FBS, MEM. The levels of SCD product, [14C]oleic acid, were determined
after separation of fatty acids on silver nitrate-impregnated TLC plates and radioactivity counting. Values represent the mean ± SD of triplicate determinations.
*P<0.01, by Student's t-test. For Western blot analysis of SCD1 (B), homogenates of preconfluent control and hSCDas-α cells were prepared by sonication on
ice. Total cellular proteins were separated by SDS-PAGE and levels of SCD1 and ß-actin were determined by Western blotting and densitometric analysis.
Table I. Fatty acid composition of total lipids from hSCDas-α
and control cells.a
–––––––––––––––––––––––––––––––––––––––––––––––––
Fatty acid (%) Control hSCDas-α
–––––––––––––––––––––––––––––––––––––––––––––––––
14:0 2.24±0.20 3.82±0.94d
16:0 24.33±0.57 29.17±2.33c
16:1 n-7 14.53±0.40 11.23±0.70b
18:0 12.02±0.38 13.28±1.10
18:1 n-9 32.61±0.76 27.15±1.86c
18:1 n-7 7.78±0.81 7.99±0.15
18:2 n-6 2.62±0.08 2.53±0.48
20:4  n-6 3.86±0.23 4.82±0.45c
16:1 n-7/16:0 060±0.01 0.39±0.01b
16:1 n-7+ 18:1 n-7/16:0 0.92±0.04 0.66±0.03b
18:1 /7-9/18:0 2.71±0.06 2.05±0.03b
MUFA/SFA 1.42±0.02 1.00±0.07b
–––––––––––––––––––––––––––––––––––––––––––––––––
aTotal cellular lipids were extracted from SCD1-depleted A549 cells
and controls and their fatty acids were converted into methyl esters
and analyzed by capillary gas chromatography. Results are expressed
as percent distribution of fatty acids and correspond to the mean ± SD
of four samples. bP<0.001; cP<0.01; dP<0.05, by the Student's t-test.
–––––––––––––––––––––––––––––––––––––––––––––––––
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In addition, the most abundant SFA, palmitic acid, was
increased by 20% in the cells deficient in SCD1 with respect
to mock-transfected cells. Consequently, the MUFA to SFA
ratio in total lipids of hSCDas-α decreased by ~30%.
Increases in myristic acid (70%) and arachidonic acid (25%)
were also observed in SCD1-deficient A549 cells. These
results clearly indicate that the total fatty acyl chain
composition of lipids in A549 cells is determined by SCD1
activity, even when these cells were grown in FBS-
supplemented medium containing MUFA.
Reduction of SCD1 expression impairs the formation of lipids
from glucose in cancer cells. Cancer cells make preferential
use of glucose as a nutrient in order to satisfy the demands of
both metabolic energy through aerobic glycolysis and
substrates for the biosynthesis of macromolecules such as
DNA, proteins and lipids (24). Importantly, glycolysis also
provides metabolites such as citrate and glycerol that will be
used for the de novo synthesis of cellular lipids. We have
previously reported that oncogene-transformed cells with
reduced levels of SCD1 exhibited an impaired lipogenesis
(16). We reasoned that glucose-mediated formation of lipids
could be a metabolic target for SCD1 in cancer cells. Thus,
cells were traced with [14C]glucose and the formation of
[14C]lipids was determined. [14C]glucose was predominantly
incorporated into the phospholipid pool of both A549 cell
groups (Fig. 2A and B), indicating that the main metabolic
fate of de novo synthesized lipid substrates is the formation of
new membrane lipids. The synthesis of phospholipids from
glucose was significantly decreased in A549 cells with a
knockdown in SCD1 with respect to controls (Fig. 2A),
suggesting that SCD1 modulates the use of glucose-derived
metabolites for the production of membrane-forming lipids in
cancer cells. The observation that the inhibition of SCD1 also
reduced the formation of energy storing lipids such as TAG
and CE (Fig. 2B) further confirms the regulatory effect of
SCD1 on the overall process of de novo lipid synthesis in
neoplastic cells.
Alterations in proliferation, programmed cell death and
anchorage-independent growth in SCD1-deficient A549 cells.
Inhibition of SCD1 gene expression in SV40-transformed
human lung fibroblasts reduces cell growth by decreasing cell
proliferation and increasing programmed cell death (20).
Hence, we asked whether human tumor-derived cells would be
equally sensitive to SCD1 depletion with respect to cell
replication and programmed cell death. As shown in Fig. 3A,
mock-transfected control cells rapidly replicated during the
course of the experiment whereas hSCDas-α cells proliferated
at a considerably reduced rate, with increasing differences
from control cells over time. In order to confirm the anti-
proliferative effect of SCD1 inhibition, we determined the rate
of DNA synthesis using [3H]thymidine as a tracer. The levels
of [3H]DNA formation were reduced in SCD1-depleted cells
by ~35% with respect to controls (Fig. 3B). Since it has been
reported that exogenous oleic acid increases proliferation in
cancer cells (26), the synthesis of DNA in cells supplemented
with 200 μM oleate was analyzed. Notably, while exogenous
oleate significantly increased the incorporation of
[3H]thymidine into newly synthesized DNA in the mock-
transfected A549 cells, the depressed DNA synthesis in
SCD1-ablated cells was not reversed by oleate treatment
(Fig. 3B), indicating that an active endogenous MUFA
synthesis is specifically required to sustain proliferation in the
lung cancer cells.
We and others have reported that SCD1 prevents
programmed cell death and lipid mediated cytotoxicity in
mammalian and human cells (20,26). Therefore, we assessed
the rate of apoptosis in A549 cells with stably reduced levels
of SCD1. We observed that the levels of fragmentation of
DNA, a measure of apoptotic damage, was increased by ~40%
in hSCDas-α cells with respect to their control counterparts
(Fig. 3C), further supporting a role of SCD1 in preventing
programmed cell death in neoplastic cells.
The above described modifications in proliferation and
death rates of A549 cells with reduced SCD1 expression led
to a significant reduction in overall cellular growth. The
population doubling time increased an average of 25% in
hSCDas-α cells compared to mock-transfected controls.
Moreover, the saturation density, another phenotypic feature
typically altered in neoplastic cells, was ~40% lower in
SCD1-ablated cells (data not shown). Taken together, these
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Figure 2. Inhibition of SCD1 expression impairs glucose-derived lipogenesis.
The rate of lipogenesis was measured in mock-transfected and SCD1-deficient
A549 cells by labeling the lipids with [14C]glucose (1 μCi/petri dish) for 6 h.
Total cell lipids were extracted and [14C]lipid fractions were detected and
quantified by TLC and radioactivity counting. PL, phospholipids; TAG,
triacylglycerols; DAG, diacylglycerol; Chol, free cholesterol; FFA, free fatty
acids and CE, cholesterylesters. Data are represented as means ± SD, n=3,
**p<0.05; *p<0.01, compared to control cells.
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observations argue for a relevant role of SCD1 in the regulation
of growth and survival of lung cancer cells.
To further explore whether the alterations in cell growth
and apoptosis in SCD1-ablated A549 cells were accompanied
by other changes in the malignant phenotype, we tested the
effects of SCD1 knockdown on anchorage-independent
growth. In order to allow the development of multicellular
colonies, cells were grown in soft agar for up to 4 weeks. As
shown in Fig. 3D, control cells were able to produce multiple
cell colonies whereas hSCDas-α cells showed a considerably
diminished number of colonies, suggesting that high levels of
SCD1 are needed to develop a full anchorage-independent
growth capacity. Moreover, MUFA synthesized by SCD1
appear to be essential lipids for sustaining this phenotypical
feature, because the addition of oleic acid to the growth
medium failed to reverse the low capability of SCD1-deficient
cells to form multicellular colonies in soft agar (Fig. 3D).
The Akt pathway is downregulated in lung cancer cells with
reduced expression of SCD1. Akt, or protein kinases B (PKB),
is a family of serine/threonine kinases that has been implicated
in several aspects of cancer development, including cell
proliferation, apoptosis and metabolic changes associated
with neoplasia such as increased aerobic glycolysis and
lipogenesis (6,27,28). Among other factors, the Akt pathway
is regulated by fatty acids. Exogenously added oleic acid, the
main product of SCD1 activity, has been shown to promote
cellular proliferation and survival through PI3K/Akt activation
in breast cancer cells, whereas palmitic acid, the main SFA in
mammalian cells, has opposite effects (29). We hypothesized
that the imbalance in SFA and MUFA content promoted by
blockade of SCD1 expression in lung cancer cells would affect
the level of phosphorylated (active) Akt. As shown in Fig. 4A,
SCD1-deficient cells exhibited a decrease of ~40% in the ratio
p-Akt to total Akt compared with mock-transfected control
cells. We also observed a ~70% decrease in p-Akt/total Akt
in SV40-transformed human lung fibroblasts with stably
reduced levels of SCD1 expression with respect to the control
cell line (Fig. 4B), suggesting that the regulation of Akt
activation is not cell-type specific. Several biological responses
to Akt activation are mediated by the inactivation of glycogen
synthase kinase-3ß (GSK-3ß), which is phosphorylated at
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Figure 3. Ablation of SCD1 gene expression reduces cell proliferation and anchorage-independent growth and increases programmed cell death. (A) Control and
hSCDas-α cells were seeded in 60-mm petri dishes and grown for up to 144 h in MEM plus 10% FBS. At different time points, cells were trypsinized and
counted in a hemocytometer. Data represent triplicate dishes. *P<0.001, by Student's t-test. (B) Preconfluent mock-transfected control and hSCDas-α cells were
pulsed with [3H]thymidine (1 μCi/dish) in 10% FBS, MEM for 2 h and 37˚C. Total [3H]-labeled DNA was precipitated and radioactivity was quantified in a
scintillation counter. Groups of cells were incubated with 200 μM oleate for 48 h previous to [3H]thymidine labeling. Values correspond to the mean ± SD of
quadruplicate dishes. Bars bearing different symbols are significantly different at p<0.001, ANOVA. (C) Programmed cell death was estimated by fragmentation
of [3H]thymidine-labeled DNA in control and hSCDas-α cells grown in MEM plus 10% FBS. Bars represent the means ± SD of quadruplicate samples. *P<0.01
by Student's t-test. (D) A549 cells (1.0x104) bearing an SCD1 gene knockdown and corresponding controls, were seeded in 60-mm dishes containing 10% FBS
MEM and 0.3% agar, with or without 200 μM oleate, over a layer of 0.6% agar. After 4 weeks, multicellular colonies were stained with ethidium bromide and
photographed under UV light. Colonies were counted on several macroscopic fields of each petri dish using a Molecular Imager Chemidoc XRS. Values
represent the mean ± SD of triplicate samples. Bars with different symbols are significantly different at p<0.05 (ANOVA).
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Ser9 by Akt (30,31). Therefore, we estimated the level of
phosphorylated GSK-3ß in hSCDas-α cells as well as in their
respective controls. As shown in Fig. 4C, phosphorylation of
GSK-3ß was significantly decreased in the SCD1-deficient
cells compared to controls, further supporting the role of
SCD1 in the regulation of the Akt activity in neoplastic cells.
To test the effect of exogenous fatty acids on Akt
activation, control and SCD1-depleted A549 cells were grown
for 24h in 0.1% FBS and then stimulated for 30 min with
0.1 mM palmitic or oleic acid bound to 0.5% BSA in FBS
depleted media as described in Materials and methods. These
conditions have been shown to be the most effective for fatty
acid-induced activation of Akt in cancer cells (25). After the
incubation with 0.1% FBS, the reduction in Akt phosphory-
lation observed in hSCDas cells with respect to control cells
remained unchanged (Fig. 5). Moreover, the reduction in Akt
phosphorylation persisted when the cells were incubated for
30 min with 10% FBS after 24 h of serum depletion (data not
shown). Treatment with palmitic acid did not affect Akt
phosphorylation in either A549 cell groups compared to BSA
treatment (Fig. 5). Interestingly, exogenous oleic acid induced
Akt activation in control cells but not in SCD1-deficient
cells, suggesting that SCD1 activity is required for fatty acid-
mediated Akt activation.
Reduced tumorigenesis in mice injected with SCD1-depleted
A549 cells. Since the knockdown of SCD1 gene expression
considerably impaired the in vitro neoplastic behavior of A549
cells, we investigated whether a reduction of SCD1 levels
would compromise the ability of these lung cancer cells to
develop tumors in mice. Hence, SCD1-deficient and control
A549 cells were injected subcutaneously into athymic nude
mice and tumor growth was determined for up to 150 days.
We observed a remarkable increase in tumor latency in tumors
originating from A549 cells with the knockdown of SCD1
expression with respect to those derived from mock-transfected
A549 (Fig. 6A). In two independent experiments, control
A549 cells formed tumors in 100% of the mice within two
weeks after cell inoculation, whereas cells with reduced SCD1
levels produced measurable tumors after ~80 days post-
injection. Strikingly, only ~40% of hSCDas-α cells produced
measurable tumors after 60 days (experiment 1) and 80 days
(experiment 2), respectively (Fig. 6A, inset), indicating that the
ablation of SCD1 activity significantly delays the formation
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Figure 4. SCD1 knockdown decreases Akt and GSK-3ß phosphorylation. Homogenates of preconfluent control and hSCDas cells were prepared. Total cellular
proteins were separated by SDS-PAGE and levels of pAkt (Ser 473) and total Akt (A and B), pGSK-3ß (Ser 9) and ß-actin (C) were determined by Western
blotting and densitometric analysis in A549 cells (A and C) or in SV40-transformed human lung fibroblasts (B). Data correspond to the mean ± SD in triplicate
samples. *P<0.05, by Student's t-test.
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of new tumors. Also noteworthy, SCD1-deficient cells were
not able to develop into tumor formations in all mice injected
with these cells. At the end of the experiments, after 150 days
of inoculation with cancer cells, 20% (experiment 1) and 40%
(experiment 2) of mice exhibited no measurable tumor masses
(Fig. 6A, inset). Additionally, we determined whether A549
cells with the knockdown in SCD1 expression would develop
tumors at a similar rate of control A549 cells. We compared
the rate of tumor growth after initial tumor appearance and
observed that tumor development was significantly reduced in
mice inoculated with SCD1-ablated cells with respect to
control cell-derived tumors (Fig. 6B), further indicating that
SCD1 is required for sustaining tumor growth. Taken as a
whole, these results strongly suggest a relevant role for SCD1
in early stages of tumor formation as well as in sustaining the
rate of tumor growth.
Discussion
In the present study, we investigated whether the inhibition
of SCD1 would modify the balance of MUFA/SFA in tumor-
forming A549 human lung adenocarcinoma cells, thereby
altering the production of lipid structures and the activation of
transduction signals that modulate cell lipid synthesis, with a
consequent impact on in vivo tumor formation. We have
previously shown that SCD1 plays a significant role in the
regulation of lipid synthesis, the rate of cell proliferation and
survival and in vitro invasiveness in human transformed cells
(4,20). Our observations that loss of SCD1 expression led to a
significant reduction in the cellular content of MUFA in
parallel with the increase in SFA levels, provide persuasive
evidence of the relevance of SCD1 as the key regulator of fatty
acid distribution in cancer cells (4,20,32). Since neoplastic
cells show an enrichment of phospholipids with MUFA that
leads to highly fluid cell membranes (4,8), the activation of
SCD1 expression may be part of a mechanism that preserves
a lipid membrane environment that would be more favorable
for growth factor-mediated proliferation (33,34) as well as for
cancer growth and invasiveness (35-37).
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Figure 5. Exogenous oleic acid does not reverse the reduced Akt phosphorylation in SCD1-deficient A549 cells. Preconfluent A549 cells were grown in 0.1%
FBS supplemented media for 24 h and then treated with 0.1 mM palmitic (Pal) or oleic acid (Ole) complexed with 0.5% fatty acid-free BSA in 0.1% FBS-
supplemented media for 30 min. The same media with no fatty acids was used as a control (BSA). Cellular levels of both phosphorylated and total Akt was
determined by Western blotting. Bands were detected with a ChemiDoc (Bio-Rad) and quantified by densitometry. Data represent mean ± SD of triplicate
samples.*P<0.05 vs. control cell line under the same treatment; †p<0.05 vs. BSA-treated control cells; #p<0.05 vs. palmitic acid-treated control cells. One Way
ANOVA and Bonferroni t-test.
Figure 6. Delayed tumor appearance and reduced rate of tumor growth in
SCD1-ablated A549 lung adenocarcinoma cells. Five mice received
subcutaneous inoculations containing 1x106 A549 cells either bearing SCD1
gene knockdown or mock-transfected controls. Tumor appearance and growth
was evaluated for up to 150 days. (A) Percentage of mice bearing detectable
tumors in two experiments. (B) Rate of tumor growth. Data correspond to the
mean ± SD of four mice inoculated with hSCD1as-α cells and five mice
injected with control cells. *P<0.05, by ANOVA.
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It has been proposed that SCD1 is a crucial factor in the
regulation of cell proliferation, programmed cell death and
fatty acid-mediated lipotoxicity (20,26,38). SCD1 expression
is triggered by growth factors in normal human cells (39-41)
and is also a critical player in neoplastic cell growth (20). Our
observation of a notable reduction in the rate of proliferation of
SCD1-ablated cells unequivocally shows that SCD1 is a main
factor in the control of cancer cell growth. Furthermore, SCD1
activity is required for the proliferative effects of exogenous
MUFA since exogenous oleate stimulated proliferation in
control A549 cancer cells, an effect previously reported for
breast cancer cells (25), whereas oleate was ineffective in
reversing the decrease in cell proliferation of SCD1-deficient
cancer cells. In addition, the finding of a greater rate of
apoptosis in SCD1-deficient A549 cells confirms previous
observations in SV40-transformed cells and in lung and colon
cancer cells in which ablation of SCD1 triggered programmed
cell death (20,42). Interestingly, the activation of SCD1 in
A549 cells appears to be part of a safeguard mechanism to
confront the toxic effects of excess endogenous and exogenous
SFA. This hypothesis is supported by the finding that a greater
rate of programmed cell death occurred when hSCDas-α cells
were cultured in medium with sufficient oleic acid. Overload
of SFA promotes metabolic conditions that trigger apoptosis in
mammalian and human cells (43), hence the antiapoptotic
effect of SCD1 may be likely caused by the conversion of
toxic excess SFA into more harmless MUFA by the desaturase
(26,38). We have previously shown that, because of their
constitutively high SCD1 expression levels, human oncogene-
transformed cells convert most of both exogenous and de novo
synthesized SFA into MUFA (4). More to this point, we
observed that when SCD1 expression was reduced in these
cells, the consequent increase in SFA content was accompanied
by a greater rate of apoptosis (20).
Anchorage-independent growth, a hallmark of malignant
transformation, was also found significantly decreased in
A549 cells with ablated expression of SCD1, further
confirming that the synthesis of MUFA is essential for
cancer cell invasiveness. However, unlike SCD1-ablated
SV40-transformed cells (20), A549 cells with a chronic
reduction SCD1 did not exhibit a total suppression of
anchorage-independent cell proliferation. This discrepancy
may lie in the fact that hSCDas-α cells showed ~20%
decrease in SCD activity compared to ~70% reduction in the
enzyme activity in SV40-cells with ablated SCD1
expression, suggesting that the alteration of the neoplastic
cellular phenotype may be dependent on the degree of SCD1
inhibition.
Endogenously produced MUFA seem to be vital not only
for cell growth but also for cancer cell invasiveness, since the
alterations in proliferation and colony formation promoted by
SCD1 ablation in A549 cells could not be overcome by
supplying abundant MUFA (~200 μM oleate) in the cell
culture medium. This result is in agreement with the
observation in SCD1 knock out mice in which the alterations
in lipid metabolism, particularly the synthesis of neutral lipids,
could not be fully reversed by excess dietary MUFA (44,45).
The reason for the divergent effects of endogenous and
exogenous oleic acid on cell metabolism is unknown. It has
been speculated that exogenous and endogenous MUFA
enter separated metabolic compartments and, hence, display
different intracellular regulatory roles (46). However, the
presence of a mechanism for such putative fatty acid
segregation awaits experimental confirmation.
Alterations in MUFA and SFA content have been
associated with cancer onset and progression. Studies
performed in humans show that unbalanced levels of stearic
acid (low) and oleic acid (high) appear positively correlated to
cancer and metastasis, although it is not known if altered
SCD1 activity alone is the cause of this imbalance (47-49).
Furthermore, SCD1 expression has been linked with critical
events of cancer development in several previous studies in
cell culture and animal models. For example, the expression of
SCD1 is increased by agents that predispose to carcinogenesis,
including dichloroacetic acid (15) and peroxisome proliferators
(46). Moreover, it was shown in mice and rats that the back-
ground level of SCD1 expression correlates with predisposition
to liver carcinogenesis; the animals with the higher levels of
SCD1 were more susceptible to chemical induction of cancer
than those with lower SCD1 (50). In the present study, we
demonstrated for the first time the direct participation of SCD1
in in vivo carcinogenesis. Stable ablation of SCD1 expression
in A549 cells resulted in a clear delay in tumor formation in
nude mice as well as in a more reduced rate of tumor growth.
As these cells were still able to make large tumors, albeit
fewer and more slowly, it is likely that other factors involved
in tumorigenesis and cancer growth are unaffected by the lack
of SCD1 expression. However, since the reduction in SCD1
expression levels was significant but moderate, a more
pronounced inhibition of MUFA synthesis may be able to
fully suppress tumor growth. Additionally, the anticancer
effect of SCD1 inhibition has also been addressed by
pharmacological inhibition of SCD enzyme activity. Sterculic
acid, a cyclopropene fatty acid with inhibitory effects on
SCD activity, has been shown to display antitumoral effects
in vitro and in a tumor model in rats (51,52) although the
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Figure 7. Hypothetical mechanism of the regulation of Akt signaling, lipid
synthesis and tumorigenesis by SCD1 in A549 lung cancer cells. Stable
inhibition of SCD1 expression promotes the downregulation of Akt activation
and lipogenesis in A549 cells. This metabolic and signaling dysregulation in
SCD1-ablated cells leads to lower rates of cell proliferation, invasiveness
and tumor formation and growth.  Exogenous MUFA are unable to reverse
the biological changes promoted by SCD1 blockade in the cancer cells.
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specificity of this effect is uncertain because this compound
also inactivates other desaturases (53).
Several potential mechanisms can be postulated to explain
the metabolic and phenotypical changes observed in SCD1-
ablated lung cancer cells that may ultimately lead to impaired
tumor formation. A possible target for the effects of SCD1
deficiency is the signaling network, particularly the PI3K/Akt
pathway, a central signaling pathway of clear relevance in
carcinogenesis that controls numerous cellular functions,
including cellular proliferation, growth, survival and mobility
(54). Components of this signaling mechanism are commonly
deregulated in cancer, including lung and breast cancer
(28,54). The regulatory role of endogenously synthesized
MUFA synthesis on Akt signaling is little known. It has been
reported that phosphorylation of Akt is upregulated in muscle
of SCD1-/- mice (55), whereas siRNA-mediated ablation of
SCD1 expression in rat muscle cells inhibited Akt
phosphorylation on Ser473 (56). In the present study, we
observed that the reduction of SCD1 expression in both A549
adenocarcinoma cells and in SV40-transformed human lung
fibroblasts led to a significant decrease in Akt phosphorylation.
Consistent with the impaired Akt activity, SCD1-ablated
cells showed a decrease in phosphorylated GSK-3ß.
Interestingly, Akt signaling is differentially modulated by
exogenous SFA and MUFA. Incubation with oleic acid
upregulates the activity of the Akt pathway in breast cancer
cells and in muscle cells (25,29,57). In contrast, exogenously
added palmitic acid inhibits Akt activation by increasing
PTEN or protein phosphatase 2A-like activity in endothelial
and muscle cells (58,59). In agreement with the afore-
mentioned study in breast cancer cells, exogenous oleic acid
induced Akt phosphorylation in mock-transfected A549 lung
cancer cells. However, our observation that, oleic acid was
unable to reverse the low Akt phosphorylation status in
SCD1-deficient cells suggests that active synthesis of MUFA
is required for the fatty acid-mediated activation of Akt
signaling.
The alterations in glucose-derived lipid synthesis
observed in SCD1-ablated cancer cells may be attributed to
the inactivation of Akt since this signaling pathway plays a
central role in the regulation of the associated processes of
glycolysis and de novo lipid synthesis in cancer cells (24). In
this connection, it has been observed that the induction of
lipogenesis in human non-transformed and cancer cells by
growth factors requires SREBP-1 activation through the
stimulation of Akt signaling cascade (6,40,41,60). SCD1
blockade may also alter cancer cell lipogenesis by affecting
crucial regulators of glycolytic flow, such as phospho-
fructokinase-1 and pyruvate kinase, as well as key enzymes
in de novo synthesis of lipids such as ATP citrate lyase,
acetyl CoA carboxylase and FAS, all of which are highly
activated in cancer cells (5,28,61). Adding to this hypothesis,
alterations in the levels of glycolytic metabolites as well as
the de novo synthesis of lipids in liver of SCD1-/- mice have
been reported (62).
The observed downregulation of Akt signaling in SCD1-
ablated cancer cells may also explain the reversion in the
cellular neoplastic phenotype since a decrease in cell
proliferation, higher rates of apoptosis and reduced
invasiveness were detected in A549 cells after inhibition of
the Akt signaling pathway (63,64). In addition, it has been
reported that pharmacological inhibition of mTOR, a
downstream effector of Akt, reduces tumor formation and
progression in several in vivo tumor models (65,66). At
present, the molecular mechanisms by which SCD1 modulates
Akt-mediated signaling mechanisms are not fully understood.
It can be speculated that in cancer cells, by changing the ration
MUFA/SFA in plasma membranes, SCD1 exercises a
modulatory influence on tyrosine kinase receptors and other
Akt-regulating signaling proteins that reside in the cell
membrane or interact with membrane lipids. Nevertheless,
experimental evidence supporting this hypothetical
participation of SCD1 in a concerted regulation of lipid
biosynthesis and Akt-mediated signaling transduction is
lacking.
In summary, based on the results presented here we
postulate that the specific inhibition of SCD1 activity in cancer
cells decreases the ratio MUFA/SFA in cell membrane lipids,
leading to inactivation of Akt signaling and impaired
lipogenesis (Fig. 7). These metabolic and signaling effects of
SCD1 blockade may promote the profound effects on cell
proliferation, programmed cell death and invasiveness and,
concomitantly, in the rates of tumor formation and tumor
growth observed in SCD1-deficient lung cancer cells. The
observation that exogenous MUFA cannot reverse the
biochemical and biological perturbations of SCD1 ablation
further underscores the relevant regulatory role of SCD1 in
cancer cell biology.
In conclusion, this is the first direct demonstration that
crucial features of malignant transformation, both in cultured
cancer cells and in tumor xenografts, are determined by the
level of SCD1 expression. These observations may shed new
light on the role of MUFA synthesis and fatty acid composition
of lipids in the control of cancer cell growth and tumor
formation and lay the groundwork to develop new strategies of
cancer therapy based on targeting SCD1 function.
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